ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
-0,15%
Euro vs US Dollar
1,07175
-0,05%
Bitcoin
66.202,00
0,30%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Grifols SA (GRFS)

  7. Grifols SA (GRFS) News

GRFS

Grifols (GRFS)

Grifols SA
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:GRFS
DatumZeitQuelleÜberschriftSymbolFirma
14/06/202423h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
04/06/202416h51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
31/05/202422h46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
19/04/202422h42PR Newswire (US)Grifols 2023 Annual Report on Form 20-F filed with the SECNASDAQ:GRFSGrifols SA
18/04/202415h30GlobeNewswire Inc.Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.NASDAQ:GRFSGrifols SA
15/04/202413h06IH Market NewsSamsung Surpasses Apple in Q1 Smartphone Market; Salesforce in Talks to Acquire Informatica, and More NewsNASDAQ:GRFSGrifols SA
04/04/202410h00GlobeNewswire Inc.Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus ScreeningNASDAQ:GRFSGrifols SA
22/03/202414h07IH Market NewsFedEx Soars 13% with Profits Above Forecasts, Nike Hit by China Slowdown, and Latest NewsNASDAQ:GRFSGrifols SA
08/03/202412h19IH Market NewsCNOOC Oil Field Discovery in South China Sea, Grifols Surges 18% After KPMG Approval, and Latest NewsNASDAQ:GRFSGrifols SA
14/02/202409h16GlobeNewswire Inc.Grifols announces positive topline phase 3 fibrinogen clinical trial resultsNASDAQ:GRFSGrifols SA
26/01/202423h14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
16/01/202412h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
12/01/202412h10IH Market NewsWall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and MoreNASDAQ:GRFSGrifols SA
10/01/202419h08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
10/01/202414h59Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
10/01/202412h21IH Market NewsWall Street Highlights: Tesla Launches Restyled Model 3, VinFast Unveils Pickup Prototype, and MoreNASDAQ:GRFSGrifols SA
09/01/202420h49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
09/01/202414h25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
29/12/202315h59Dow Jones NewsGrifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down DebtNASDAQ:GRFSGrifols SA
29/12/202315h46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
29/12/202315h40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
16/11/202311h00PR Newswire (US)Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patientsNASDAQ:GRFSGrifols SA
15/11/202314h00GlobeNewswire Inc.Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin DeficiencyNASDAQ:GRFSGrifols SA
06/11/202314h00GlobeNewswire Inc.GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023NASDAQ:GRFSGrifols SA
02/11/202318h25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
25/10/202300h30GlobeNewswire Inc.Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTADNASDAQ:GRFSGrifols SA
20/10/202314h36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
19/10/202314h00GlobeNewswire Inc.GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum NeurotoxinsNASDAQ:GRFSGrifols SA
28/09/202314h00GlobeNewswire Inc.GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564NASDAQ:GRFSGrifols SA
01/08/202314h00GlobeNewswire Inc.Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and AnalyticsNASDAQ:GRFSGrifols SA
 Showing the most relevant articles for your search:NASDAQ:GRFS

Kürzlich von Ihnen besucht

EU
ALBOO
BOOSTHEAT
NEO
GBFB
GuardBonds 2025 Investme...
NYSE
ORCL
Oracle
LSE
QED
Quadrise
LSE
CAPC
Capital & Counties Prope...
ASX
YTMVCX
Equity Trustees
BIT
F18694
Vontobel Financial Produ...
USOTC
BMRPF
B and M European Value R... (PK)
COIN
CBUCKSGBP
CRYPTOBUCKS
ASX
RADO
Radiopharm Theranostics
COIN
MADTETH
MADToken
BIT
P1Z273
NLBNPIT1Z273 20991231 50...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten